HER2-targeted radioimmunotherapy regimen achieves complete and durable response in breast cancer model

A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast ...

Advanced breast cancer patients living longer thanks to improvements in treatment and care

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the ...
ascopubs.org

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis ...

NOTE. Percentage values in the cells may not sum up to 100% because of rounding. Bold indicates P < .05. Abbreviations: Bev, bevacizumab; ECOG-PS, Eastern Cooperative Oncology Group Performance Status ...
ascopubs.org

Treatment Patterns and Outcomes of Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in Tanzania

A retrospective hospital-based study was conducted between January 2018 and May 2021 at two prominent public tertiary hospitals in Tanzania. The primary outcome was the 5-year overall survival (OS) ...
Cure Today

A Patient Guide to Understanding HER2-Positive Breast Cancer

HER2-positive breast cancer is driven by HER2 protein overexpression, historically linked to poor outcomes but now improved by targeted therapies. Treatment varies by stage, involving surgery, ...